Zoetis Inc (NYSE:ZTS) EVP Catherine A. Knupp sold 28,563 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $119.91, for a total transaction of $3,424,989.33. Following the completion of the transaction, the executive vice president now owns 78,616 shares of the company’s stock, valued at $9,426,844.56. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of NYSE ZTS opened at $119.91 on Tuesday. The firm’s 50-day moving average price is $122.50 and its 200-day moving average price is $118.46. The company has a quick ratio of 3.02, a current ratio of 4.39 and a debt-to-equity ratio of 2.47. The company has a market cap of $57.40 billion, a PE ratio of 38.31, a PEG ratio of 2.76 and a beta of 0.80. Zoetis Inc has a 52-week low of $78.90 and a 52-week high of $130.20.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.58 billion. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.83 EPS. As a group, equities research analysts anticipate that Zoetis Inc will post 3.6 EPS for the current fiscal year.
Several brokerages recently issued reports on ZTS. Craig Hallum increased their price target on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. ValuEngine lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Goldman Sachs Group assumed coverage on shares of Zoetis in a research report on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 price objective on the stock. Stifel Nicolaus set a $140.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, September 13th. Finally, Barclays increased their price objective on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $125.20.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tarbox Family Office Inc. boosted its holdings in shares of Zoetis by 74.4% during the 3rd quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock valued at $27,000 after acquiring an additional 93 shares during the last quarter. Prestige Wealth Management Group LLC purchased a new stake in shares of Zoetis during the 2nd quarter valued at about $27,000. Tradewinds Capital Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. Altshuler Shaham Ltd boosted its holdings in shares of Zoetis by 198.8% during the 2nd quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock valued at $29,000 after acquiring an additional 169 shares during the last quarter. Finally, Atlas Capital Advisors LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $33,000. 90.17% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: What are different types of coverage ratios?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.